Methotrexate Pfizer Healthcare Ireland (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for making tetrahydrofolate. This limits the synthesis of DNA, RNA and proteins, especially in rapidly dividing cells such as cancer cells and activated immune cells, thereby reducing inflammation and tumor growth.

The specific dose of Methotrexate is determined by the prescribing clinician based on the patient’s condition, weight, renal function and treatment goals. Dosage regimens can vary widely, and the prescriber will tailor the schedule to achieve the best therapeutic effect while minimizing risk.

Methotrexate is contraindicated in pregnancy because it can cause fetal malformations and miscarriage. It is also not recommended while breastfeeding, as it may be excreted in breast milk and affect the infant. Women of child‑bearing potential should use effective contraception during treatment and for a period after discontinuation.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Methotrexate is a conventional synthetic DMARD that is often used as a first‑line agent because of its broad efficacy and lower cost compared with biologic therapies such as TNF‑α inhibitors. Biologics target specific cytokines and may be chosen when patients do not respond adequately to methotrexate or experience intolerable side effects.

Methotrexate should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Ensure the container is tightly closed and keep it out of reach of children. Do not freeze the product.

Methotrexate is supplied as a sterile injectable solution and can be given via intra‑arterial, intramuscular or intrathecal routes, depending on the indication and clinical protocol. Administration is performed by a qualified healthcare professional under aseptic conditions.

The most serious adverse events include severe liver toxicity, pulmonary fibrosis, profound bone‑marrow suppression leading to pancytopenia, acute renal failure, and life‑threatening cutaneous reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for early signs of these complications.

Methotrexate is contraindicated in pregnant women, individuals with severe renal or hepatic impairment, and patients with known hypersensitivity to the drug. It should also be avoided in patients with active infections or those receiving certain interacting medications without close monitoring.